NeOnc Showcases Two Brain Cancer Drug Programs at SNO as FDA Meetings Approach
NeOnc Technologies Holdings Inc(US:NTHI) Globenewswire·2026-11-13 21:52DENVER, Nov. 13, 2026 (GLOBE NEWSWIRE) -- (247MarketNews) — NeOnc Technologies Holdings (NASDAQ: NTHI) reaches an important clinical-development milestone today as it presents updated findings from two investigational brain cancer programs at the 31st Annual Meeting of the Society for Neuro-Oncology (SNO) in Philadelphia. The presentations put the company's intranasal NEO100 and oral NEO212 programs in focus, with additional clinical evidence arriving as NeOnc prepares for important FDA discussions and cont ...